Kortenberg

Researchers are investigating the effectiveness and cost-effectiveness of Attachment Based Family Therapy (ABFT) compared to Treatment As Usual (TAU) for young adults aged 18 to 25 who experience frequent suicidal thoughts. This mental health issue is a serious concern worldwide, especially in Belgium and the Netherlands, where suicide is a leading cause of death among young adults. Current treatments have limited success, and this study aims to see if ABFT, which focuses on improving family relationships, can better reduce suicidal thoughts and behaviors and support young adults and their families. The study is a randomized controlled trial involving 138 participants from multiple sites including hospitals, mental health centers, and private practices in Belgium and the Netherlands. Participants are assigned to either ABFT plus TAU or TAU alone. ABFT is a manualized therapy that strengthens parent-child attachment to create a secure support base, delivered in weekly sessions over about 16 weeks. TAU consists of existing standard treatments such as antidepressants, cognitive behavioral therapy, or dialectical behavior therapy, with limited family therapy. Parents or caregivers may be involved in both treatments. Participants will be assessed at baseline, immediately after treatment, and at 3, 6, and 12 months follow-up to measure changes in suicidality using questionnaires and therapist reports. Researchers will also evaluate cost-effectiveness, family functioning, depressive symptoms, and treatment adherence. The study aims to improve clinical guidelines and policymaking to enhance care for suicidal young adults and their families over a one-year period.

This trial focuses on patients with difficult-to-treat depression who do not show early improvement during an acute course of electroconvulsive therapy (ECT). Researchers aim to find out whether continuing right unilateral (RUL) ECT or switching to bitemporal (BT) ECT helps patients recover faster and has less effect on memory. The study also tracks depressive symptoms and cognitive function up to three months after treatment. Participants who have less than a 50% improvement in depressive symptoms after four ECT sessions will be randomly assigned to either continue with RUL ECT or switch to BT ECT. Both treatments use different electrode positions on the ECT device. Assessments occur at baseline, after 4 sessions before randomization, after 8 sessions, at the end of the acute treatment (up to 7 weeks), and three months later. During the study, mood and memory tests will be performed to monitor changes in depression severity and autobiographical memory. These evaluations take place multiple times during and after the acute ECT course. The primary outcomes include changes in depressive symptoms and memory function at specified intervals, ensuring careful monitoring of both treatment effectiveness and cognitive safety.